Matthew Rhadans, MD
Family Medicine · Higginsville, MONPI 1073874905
Payments from drug & device makers
Across 293 payments — averaging $16.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AbbVie$582
- AstraZeneca$489
- Lilly USA, LLC$380
- Amgen$250
- Boehringer Ingelheim$212
- plus $2K from 23 others
What the payments were for
- Food & beverage$4,70199%
- Education$251%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 79 | $1,087 |
| AbbVie(2 entities) | 34 | $582 |
| AstraZeneca(2 entities) | 27 | $489 |
| Lilly USA, LLC | 25 | $380 |
| Amgen | 17 | $250 |
| Boehringer Ingelheim | 13 | $212 |
| Teva Pharmaceuticals USA, Inc. | 13 | $199 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $188 |
| Dexcom, Inc. | 7 | $180 |
| Johnson & Johnson | 10 | $152 |
| Novartis | 9 | $138 |
| E.r. Squibb & Sons, L.L.C. | 6 | $112 |
| Astellas Pharma US Inc | 5 | $95 |
| Merck | 6 | $92 |
| Exact Sciences | 5 | $76 |
| Abbott | 4 | $62 |
| Otsuka America Pharmaceutical, Inc. | 3 | $61 |
| Pfizer | 4 | $60 |
| Boston Scientific | 3 | $50 |
| Eisai Inc. | 3 | $47 |
| Hologic Sales And Service, LLC | 2 | $40 |
| Sanofi-aventis U.S. LLC | 1 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $30 |
| Tonix Medicines, Inc. | 1 | $23 |
| Vertex | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Bayer | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| Philips North America LLC | 1 | $13 |
How this compares
$4,726 in reported general payments places this provider in the 85th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 235 | $281,229 |
| EliquisApixaban | 261 | $169,567 |
| JardianceEmpagliflozin | 218 | $150,143 |
| LinzessLinaclotide | 182 | $107,392 |
| XifaxanRifaximin | 30 | $102,861 |
| TrulicityDulaglutide | 75 | $82,601 |
| XareltoRivaroxaban | 137 | $81,559 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 113 | $77,113 |
| Tresiba Flextouch U-100Insulin Degludec | 99 | $69,638 |
| MyrbetriqMirabegron | 138 | $51,714 |
| JanuviaSitagliptin Phosphate | 81 | $35,100 |
| EntrestoSacubitril/Valsartan | 36 | $33,340 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 231 | $21,236 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 36 | $21,035 |
| VraylarCariprazine Hcl | 12 | $17,077 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,087 | $281,229235 claims |
| PfizerEliquis, Lyrica | $60 | $175,849272 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $212 | $171,178254 claims |
| AbbVieLinzess, Vraylar | $582 | $124,469194 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance | $30 | $117,91955 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $380 | $98,78390 claims |
| Johnson & JohnsonXarelto | $152 | $81,559137 claims |
| Astellas Pharma US IncMyrbetriq | $95 | $51,714138 claims |
| MerckJanuvia | $92 | $35,10081 claims |
| NovartisEntresto | $138 | $33,34036 claims |
| AstraZenecaByetta, Symbicort | $489 | $16,50239 claims |
| AmgenCorlanor | $250 | $7,60512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Higginsville
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.